EarlyCDT Lung Partnership Contract Signed Reports Oncimmune Holdings

GenesisCare Orders 27 Elekta Flexitron Treatment Devices

Elekta (EKTA-B.ST) announced today that GenesisCare, a leading global provider of integrated cancer care, has ordered 27 Flexitron® brachytherapy afterloader systems, including service agreements. The...

FoodMarble AIRE Shown to Exceed the Performance of ‘Gold Standard’ SIBO Testing in Clinical Trial

SIBO is a very common disorder where there are excessive bacteria present in the small intestine. The true prevalence of SIBO in the general population is largely unknown, with some studies estimating its occurrence in up to 15% of healthy individuals. It is also largely associated with many other common clinical conditions, including irritable bowel syndrome, where 40-80% of IBS patients have SIBO.

AAOS on IPO Elimination Reversal in 2022 CMS Outpatient Rule

AAOS is encouraged to hear that CMS has heeded the patient safety concerns of the physician community regarding the abrupt elimination of the Inpatient Only.

Oncimmune Holdings plc today announces that it has signed a foothill contract to utilize the Company’s EarlyCDT Lung panel to detect incident lung cancer cases in a screening setting.

With one of the world’s largest pharmaceutical companies, Oncimmune will further evaluate EarlyCDT Lung for the detection of lung cancer in at-risk patients. The initial phase of the collaboration will assess the utility of Early CDT Lung test at detecting incident lung cancer cases in a screening setting.

We expect this initial phase to be the first step towards a long term partnership to generate widespread availability of the EarlyCDT Lung test to improve early detection of lung cancer and facilitate earlier treatment.

Adam M Hill, CEO of Oncimmune said: “Over the past two months we have announced commercial contracts which touch upon the full breadth of Oncimmune’s commercial offering.  Our three-year strategy, announced in late 2018, centered on identifying and capitalizing upon the wide range of opportunities presented by Oncimmune’s proprietary autoantibody-based platform. We firmly believe that the momentum we are building validates our strategy and underpins the commercial potential of our business.

We look forward to delivering this work over the coming weeks and announcing the further development of this partnership.”

spot_img

DON'T MISS

Dr. Woodrow Myers Joins the Freespira Board of Directors

Former Blue Cross Blue Shield Health Plan chief medical officer and chief healthcare strategist brings clinical, quality and business insights to fast-growing digital therapeutic company.

Avanos Medical, Inc. Appoints Moji James as Senior Vice President & General Counsel

Prior to Tmunity, James served as senior vice president and general counsel of Iroko Pharmaceuticals, and she began her life sciences legal career at Wyeth Pharmaceuticals (now part of Pfizer).

Our Sister Publication: Biotechnology News Magazine

Subscribe to Medical Device News Magazine here.